Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17876407 | 0.94 | PARP1 (0.37) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL17875575 | 0.92 | RAB9A (0.38) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL16325179 | 0.88 | HTR2A (0.40) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL16361856 | 0.88 | HTR2A (0.40) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL1833547 | 0.87 | PARP1 (0.50) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL17875571 | 0.82 | PARP1 (0.44) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL16361854 | 0.80 | CTNNB1 (0.37) | HTR2AHTR2CMAPT | |
| SCHEMBL16323362 | 0.80 | CTNNB1 (0.37) | HTR2AHTR2CMAPT | |
| SCHEMBL16362041 | 0.79 | DRD1 (0.49) | PARP1SLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL1840364 | 0.79 | DRD1 (0.45) | PARP1SLC6A2SLC6A4HRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579641-B2 | Aryl phosphines with fused ring ortho-alkoxy substitution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2014205025-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184811-A1 | ARYL PHOSPHINES WITH FUSED RING ORTHO-ALKOXY SUBSTITUTION | ALK, PHOSPHO1, MPL | PARP1 3058/4885SLC6A2 2602/4885SLC6A4 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.